Nextech Invest
Melissa McCracken, Ph.D., joined Nextech Invest Ltd. in 2019. Melissa is a scientist by training with a passion for emerging technologies in cancer therapies. Melissa is a board member of TYRA Biosciences, board observer of IconOvir, and a previous board member of ImaginAb and board observer of Silverback Therapeutics.
Prior to Nextech, Melissa was a senior associate at Third Rock Ventures focusing on scientific due diligence, partnership development and new company formation in oncology and immunology. Melissa helped build and launch Celsius Therapeutics, a company focused on discovering precision therapeutics for oncology and autoimmune. Melissa has also worked within larger biotech organizations completing multiple internships in research and development at Amgen (NASDAQ: AMGN).
Melissa holds a B.S. in biochemistry and molecular biology from University of California, Davis, a Ph.D. in molecular and medical pharmacology from University of California, Los Angeles with her research focused on engineered immunity for cancer. Melissa also completed a postdoctoral fellowship at Stanford University where her research focused on immuno-oncology.
This person is not in any offices
Nextech Invest
Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. They focus almost exclusively on oncology therapeutics, and on helping to drive value creation for their portfolio companies. They invest in the most promising drug discovery companies with the potential to create multiple medicines. Their portfolio is focused throughout the US and Europe with investments from company inceptions to crossover rounds.